Showing 850 results
-
Media Release /The analysis determined that Entresto benefited patients considered clinically stable, with no history or only a remote history of prior heart failure hospitalization, just as much as it did those…
-
Media Release /- Late-breaking data at AAD show Cosentyx® remains superior to Stelara® in achieving almost clear skin (PASI 90) at Week 16 and at one year in 76.2% versus 60.6% of moderate to severe psoriasis…
-
Media Release /In advanced progressive, nonfunctional NET, Afinitor is the first approved treatment for patients with lung NET and the first oral therapy for GI NETApproval helps fulfill unmet need as progressive,…
-
Media Release /Three leading US cardiology societies have jointly issued a clinical practice guideline update that has redefined standard of care treatment for heart failure and given Entresto® a strong Class I…
-
Media Release /Novartis has established FortiHFy, the largest global clinical program in the heart failure disease area, comprising over 40 active or planned clinical studies designed to generate an array of…
-
Media Release /-- Subject to approvals, Ilaris® (canakinumab) will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF-- Designations support…
-
Media Release /- Global survey, including more than 1,400 U.S. moderate-to-severe psoriasis patients, is the first to look at perceptions of clear skin1- Despite the significant impact of living with the disease,…
-
Media Release /Findings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors)(1)Cardiology experts highlight risk of…
-
Media Release /- Data demonstrate at 12 months, 81% of patients started on fingolimod stay on therapy vs. 29% started on injectable disease-modifying therapies (iDMTs)(1)- Injectable disease-modifying therapies are…
-
Media Release /-- EXPAND study data presented at ECTRIMS 2016 show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs. placebo in patients with…
